Grasp five factors to promote the healthy development of biotechnology and industry in China

[China Pharmaceutical network industry trends] although the development of life science research and biotechnology in China started late, it developed rapidly and made many remarkable achievements It not only made important contributions to economic and social development, but also played an important role in promoting China's international influence However, compared with the world's advanced countries, China's overall level is still far behind How to further promote the development of biotechnology in China? (grasp the five elements to promote the healthy development of biotechnology and industry in China) is a strategic design A country's biotechnology development needs a national level strategic planning and design, which is now often called top-level design, but the top-level design needs to be carried out in the macro thinking, that is, focusing on strategic consideration and planning, focusing on the key, highlighting the key, rather than comprehensive layout and laying the foundation for the future establishment of specific projects First of all, it is necessary to make clear the international position of biotechnology in China, that is, where it is ranked At present, China has made important progress in the construction of an innovative country There are relatively in-depth and clear research results on the international position of China's scientific and technological innovation capacity, but there is no systematic research and positioning on China's position in the world of biotechnology Scientific American has evaluated and ranked the development strength of biotechnology in 54 countries in the world McKinsey Research Institute has compared various fields including biotechnology between China and the United States The technical prediction of biotechnology field organized by China Biotechnology Development Center has also conducted preliminary comparative research on the development degree of biotechnology between China and the United States The results of the previous studies are quite different Therefore, we need to organize and carry out an in-depth and systematic evaluation study on the international competitiveness of biotechnology, find out the gap between China and the advanced countries, carry out the strategic design in the field of biotechnology, and put forward the macro guidelines for the development of biotechnology in China The second is demand orientation The defects of our country's independent innovation ability of biotechnology and lack of core key technologies are still outstanding For example, in stem cell research, although Chinese scientists are at the forefront of the world in proving the properties of iPS cells and obtaining pluripotent stem cells by inducing small molecular compounds, iPS cell technology is initiated by Japan, and its core key technologies are basically controlled by Japan and the United States Therefore, we need to start from the key needs, strengthen the key technology research and independent innovation, pay attention to the basic science and frontier technology research, deploy the innovation chain around the industrial chain, rely on the implementation of the national science and technology plan, advance the deployment in key areas, capture a number of key generic technologies with overall and driving characteristics, and own a number of independent intellectual property rights For example, in the field of stem cells and regenerative medicine, we should focus on breaking through the exploration of pluripotent markers of stem cells and the standardized production technology of clinical stem cells, encourage the cross fusion of stem cell technology and tissue engineering technology, and promote the development of regenerative medicine; In the field of bio agriculture, we should focus on breaking through the industrialization technology of molecular breeding technology, bio pesticide, bio fertilizer and other green agricultural biological products, developing new varieties of agriculture and forestry with high yield, and promoting the sustainable development of green agriculture; in the field of bio manufacturing, we should focus on breaking through the synthetic biological technology and bio chemical engineering technology, and realizing the clean, renewable and industrial production mode; In the field of biological environmental protection, we should focus on the breakthrough of microbial carbon dioxide fixation technology, soil heavy metal bioaccumulation technology and Biodegradation Technology, so as to provide reliable technical means for solving environmental pollution The third is market allocation Through deepening the reform of science and technology system, opening the channel between science and technology and economic and social development, giving full play to the role of market allocation, establishing a mechanism to make the market truly become the decision of technological innovation projects and resource allocation, and making enterprises truly become the main body of technological innovation In this respect, we can also learn from foreign experience to guide and promote the agglomeration development of biological industry For example, at present, there are 179 provincial-level parks in China that develop biomedicine as one of the main industries, contributing more than 30% to the output value of the national biological industry, and the aggregation effect has initially appeared Therefore, we can further rely on the biomedical park, strengthen the construction of incubator and public service platform, support the development of innovative small and medium-sized enterprises, establish industry university research alliance, promote the personnel flow among scientific research institutions, universities and enterprises, strengthen the incubation and transformation of biomedical achievements, and promote the sustainable development of regional economy and biomedical industry The fourth is to follow the law The R & D investment of biotechnology products is large, the cycle is long and the risk is high In the world, it usually takes more than 10 years and more than US $1 billion to invest in new biotechnological drugs from the start of R & D to the launch of products After the launch of products, the benefits will last for a long time and the benefits will be high This kind of biotechnological achievements and products have obvious lag characteristics For the innovative R & D of biotechnology, the evaluation content and method should not be the same as that of other types of R & D projects The evaluation system should follow the development law of biotechnology, establish an objective and practical R & D evaluation system of biotechnology In view of the characteristics of long R & D period and strong dependence on key technologies, it should be oriented to regenerative medicine, vaccines, antibodies, biochemistry, etc We will provide long-term and stable support for R & D of some major technical products It is necessary to establish an evaluation system suitable for the characteristics of different biotechnological projects In the process of evaluation and acceptance of R & D projects, classification evaluation, two-way evaluation, third-party evaluation and user evaluation should be used to make the evaluation of R & D projects more just, scientific and meet the needs of economic and social development The fifth is to make good use of talents From the perspective of the needs of biotechnology and industrial development in China, talent is still scarce According to the Nobel Prize, Lasker prize, Wolff prize, kraft prize and other influential international awards in the field of biology and medicine, only 5 scientists in China have won the above awards Therefore, it is necessary to continue to highlight the policy, take biotechnology and industrial demand as the guide, and rely on the country in accordance with the national medium and long term biotechnology talent development plan (2010-2020) Major science and technology plans and talent projects will further increase the introduction of overseas outstanding talents, high-level innovation and entrepreneurship talents, leading talents and team core talents, and support young scientists to be selected into various talent plans On the basis of in-depth implementation of the talent plan, we will further improve the policy incentive mechanism and supporting conditions of "introduction, retention and good use", so as to create a good environment for the development of leading and innovative talents.